Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Aug 13;3(15):2337-2341.
doi: 10.1182/bloodadvances.2019000052.

Validation of genetic associations with acute GVHD and nonrelapse mortality in DISCOVeRY-BMT

Hancong Tang  1 , Theresa Hahn  2 , Ezgi Karaesmen  1 , Abbas A Rizvi  1 , Junke Wang  1 , Sophie Paczesny  3 , Tao Wang  4   5 , Leah Preus  1 , Qianqian Zhu  6 , Yiwen Wang  1 , Christopher A Haiman  7 , Daniel Stram  7 , Loreall Pooler  7 , Xin Sheng  7 , David Van Den Berg  7 , Guy Brock  8 , Amy Webb  8 , Marcelo C Pasquini  4 , Philip L McCarthy  2 , Stephen R Spellman  9 , Lara E Sucheston-Campbell  1   10
Affiliations
Comment

Validation of genetic associations with acute GVHD and nonrelapse mortality in DISCOVeRY-BMT

Hancong Tang et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: S.P. has a patent on “Methods of detection of graft-versus-host disease” (US 20130115232A1, WO2013066369A3) licensed to Viracor-IBT Laboratories. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Validation in DISCOVeRY-BMT of significant SNP associations in Martínez-Laperche et al report. This figure shows the ORs, 95% CIs, and P values as reported by Martínez-Laperche et al (literature) and validation of these associations in DISCOVeRY-BMT cohort 1 and cohort 2. Martínez-Laperche et al reported 6 SNPs with P < .05 and 95% CIs that did not include OR = 1, which are shown along the y-axis. The results are grouped by those shown in the Martínez-Laperche et al report (literature) and DISCOVeRY-BMT (cohort 1 and cohort 2), as indicated in the gray boxes displayed along the top of the figure. Each circle, square, and triangle represents an OR from regression analysis, with the shapes corresponding to grade 2 to 4 aGVHD, grade 3 to 4 aGVHD, or NRM, respectively. The colors represent P values of the analyses: .05 > P ≥ .01 (blue) and P > .05 (red). rs2275913 and rs3819024 are donor variants; the remaining 4 SNPs are recipient associations. *SNPs with a 5% and **SNPs with a 10% difference in minor allele frequency (MAF) between DISCOVeRY-BMT and GETH, respectively; all other MAFs were comparable between the groups. For example, (recipient) SNP rs4711998 was associated with increased risk of grade 2 to 4 aGVHD in GETH (blue and to the right of OR = 1) but resides on OR = 1 and P > .05 in DISCOVeRY BMT.
See this image and copyright information in PMC

Comment on

  • A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms.
    Martínez-Laperche C, Buces E, Aguilera-Morillo MC, Picornell A, González-Rivera M, Lillo R, Santos N, Martín-Antonio B, Guillem V, Nieto JB, González M, de la Cámara R, Brunet S, Jiménez-Velasco A, Espigado I, Vallejo C, Sampol A, Bellón JM, Serrano D, Kwon M, Gayoso J, Balsalobre P, Urbano-Izpizua Á, Solano C, Gallardo D, Díez-Martín JL, Romo J, Buño I; GVHD/Immunotherapy Committee of the Spanish Group for Hematopoietic Transplantation. Martínez-Laperche C, et al. Blood Adv. 2018 Jul 24;2(14):1719-1737. doi: 10.1182/bloodadvances.2017011502. Blood Adv. 2018. PMID: 30030270 Free PMC article. Clinical Trial.

References

    1. Martínez-Laperche C, Buces E, Aguilera-Morillo MC, et al. ; GVHD/Immunotherapy Committee of the Spanish Group for Hematopoietic Transplantation . A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. Blood Adv. 2018;2(14):1719-1737. - PMC - PubMed
    1. Igl BW, Konig IR, Ziegler A. What do we mean by “replication” and “validation” in genome-wide association studies? Hum Hered. 2009;67(1):66-68. - PubMed
    1. Sucheston-Campbell LE, Clay A, McCarthy PL, et al. . Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime? Curr Hematol Malig Rep. 2015;10(1):45-58. - PMC - PubMed
    1. Zhu Q, Yan L, Liu Q, et al. . Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation. Blood. 2018;131(22):2490-2499. - PMC - PubMed
    1. Karaesmen E, Rizvi AA, Preus LM, et al. . Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. Blood. 2017;130(13):1585-1596. - PMC - PubMed

Publication types